TY - JOUR
T1 - Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders
AU - Akaishi, Tetsuya
AU - Misu, Tatsuro
AU - Takahashi, Toshiyuki
AU - Takai, Yoshiki
AU - Nishiyama, Shuhei
AU - Fujimori, Juichi
AU - Ishii, Tadashi
AU - Aoki, Masashi
AU - Fujihara, Kazuo
AU - Nakashima, Ichiro
N1 - Funding Information:
This work was supported by MHLW Program Grant Number 20FC1030 and JSPS KAKENHI Grant Number 20K07892 .
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/2/15
Y1 - 2021/2/15
N2 - The progression pattern of neurological disability among patients with anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) was evaluated. Neurological disability was evaluated annually for 408 person-years in 50 patients. More than 30% of the patients had clinical relapses in the first 5 years. Disability progression independent of relapse activity (PIRA) was not seen, whereas a stepwise disability progression was observed after clinical attacks in some instances. Disability worsening was more frequent after relapses than after the onset episode (p < 0.01). Similar to patients with anti-aquaporin-4 antibodies, attack-related stepwise disability progression without PIRA is typical in MOGAD, suggesting the importance of relapse prevention.
AB - The progression pattern of neurological disability among patients with anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) was evaluated. Neurological disability was evaluated annually for 408 person-years in 50 patients. More than 30% of the patients had clinical relapses in the first 5 years. Disability progression independent of relapse activity (PIRA) was not seen, whereas a stepwise disability progression was observed after clinical attacks in some instances. Disability worsening was more frequent after relapses than after the onset episode (p < 0.01). Similar to patients with anti-aquaporin-4 antibodies, attack-related stepwise disability progression without PIRA is typical in MOGAD, suggesting the importance of relapse prevention.
KW - Disability progression
KW - MOG antibody-associated disorders
KW - Myelin-oligodendrocyte glycoprotein (MOG)
KW - Neuromyelitis optica spectrum disorders
KW - Relapses
UR - http://www.scopus.com/inward/record.url?scp=85098543284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098543284&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2020.577467
DO - 10.1016/j.jneuroim.2020.577467
M3 - Article
C2 - 33388541
AN - SCOPUS:85098543284
SN - 0165-5728
VL - 351
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
M1 - 577467
ER -